Maruzzo, Marco http://orcid.org/0000-0002-6256-9249
Pierantoni, Francesco
Bortolami, Alberto
Palleschi, Dario
Zivi, Andrea
Nicodemo, Maurizio
Sartori, Donata
De Vivo, Rocco
Zustovich, Fable
Bimbatti, Davide
Pastorelli, Davide
Vultaggio, Giuseppe Dione
Soraru’, Mariella
Ballestrin, Melissa
Modonesi, Caterina
Randisi, Paola
Barile, Carmen
Perri, Gino
Basso, Umberto
Zagonel, Vittorina
Article History
Accepted: 16 May 2022
First Online: 25 June 2022
Declarations
:
: This research received "Ricerca Corrente" funding from the Italian Ministry of Health to cover publication costs.
: MM received consulting or advisory board fees from Bristol Myers Squibb, Janssen Cilag, Astellas, IPSEN, Merck Serono, MSD, and Pfizer. VZ received consulting or advisory board fees from Bristol Myers Squibb, Janssen Cilag, Astellas, IPSEN, Roche, MSD, Lilly, and AstraZeneca. The other authors FP, AB, DP, AZ, MN, DS, RDV, FZ, DB, DP, GDV, MS, MB, CM, PR, CB, GP, and UB have disclosed no conflicts of interest that are relevant to the contest of this manuscript.
: The study was coordinated by the Istituto Oncologico Veneto (IOV), and was approved by the Ethical Committee on February 10, 2020, with consent to participate and for publication.
: The original dataset was collected and stored by MM, who is responsible for the data’s integrity.
: Study conceptualization and design: MM, VZ, UB, AB; Data acquisition: DP, AZ, MN, DS, RDV, CM, FZ, PR, CB, DP, GDV, MS, GP; Statistical analysis: FP, MB, UB.; Interpretation of the data: All authors; Drafting of the manuscript: MM, FP, UB, MB; Critical revision of the manuscript for important intellectual content: All authors; Final approval of the manuscript: All authors.